

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PROLLENIUM US INC.,
Petitioner

v.

ALLERGAN INDUSTRIE, SAS,
Patent Owner

Case IPR2020-00084
Patent 9,089,519

PATENT OWNER ALLERGAN INDUSTRIE SAS'S

MANDATORY NOTICES

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, the patent owner, Allergan Industrie, SAS (“Patent Owner”), hereby submits the following Mandatory Notices in response to the Petition for *Inter Partes* Review of U.S. Patent No. 9,089,519 (“the ‘519 patent”).

1. Real Party-In-Interest under 37 CFR § 42.8(b)(1)

Each of Allergan Industrie, SAS; Allergan USA, Inc.; Allergan Sales, LLC; Allergan Holdings France SAS; Allergan Holdings Limited; Allergan Holdings, Inc.; Allergan Puerto Rico Holdings, Inc.; and Allergan, Inc. are the real parties-in-interest in this proceeding.

2. Related Matters under 37 CFR § 42.8(b)(2)

The following judicial or administrative matters may affect or be affected by a decision in this proceeding: Allergan USA, Inc. and Allergan Industrie SAS v. Prolenium US Inc. and Prolenium Medical Technologies Inc., Civil Action No. 19-126-CFC (D. Del.).

The ‘519 patent claims priority to U.S. 8,357,795 (“the ‘795 patent”). The ‘795 patent was previously asserted by the Patent Owner and its affiliates in an Amended Complaint filed on December 6, 2013 in Allergan USA, Inc., et al. v.

Medicis Aesthetics, Inc., et al., 8:13-cv-01436-AG-JPR, in the U.S. District Court for the Central District of California, dismissed with prejudice June 12, 2015.

The ‘795 patent also was the subject of (a) IPR2014-01422 filed August 29, 2014 and terminated June 19, 2015 by way of joint motion to terminate, and (b) IPR2017-02003 filed August 2, 2017 and denied on March 9, 2018.

U.S. 8,822,676 (“the ‘676 patent”) claims priority to the ‘519 patent and is the subject of an IPR petition filed by Petitioner. The ‘676 patent is also the subject of the aforementioned civil action.

Petitioner has also filed IPR petitions against U.S. 8,450,475, U.S. 8,357,795, U.S. 9,358,322, and U.S. 9,238,013, each of which is the subject of the aforementioned civil action.

3. Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)

Patent Owners designate the following lead and back-up counsel:

LEAD COUNSEL	BACK-UP COUNSEL
Dorothy P. Whelan, Reg. No. 33,814 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: 612-335-5070/Fax 877-769-7945 IPR13351-0081IP1@fr.com	Michael J. Kane, Reg. No. 39,722 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: 612-335-5070/Fax 877-769-7945 PTABInbound@fr.com

4. Service Information under 37 CFR § 42.8(b)(4)(i) *et seq.*

Please address all correspondence and service to both counsel as listed above. Patent Owner consents to service by email at IPR13351-0081IP1@fr.com (ref.: Docket No. 13351-0081IP1).

Respectfully submitted,

Date: October 30, 2019

/Dorothy P. Whelan/
Dorothy P. Whelan, Reg. No. 33,814

Customer Number 26191
Fish & Richardson P.C.
Telephone: (612) 335-5070
Facsimile: (877) 769-7945

